Preclinical pharmacokinetics and pharmacodynamics of apixaban, a potent and selective factor Xa inhibitor

European Journal of Drug Metabolism and Pharmacokinetics

Volumn 36, Issue 3, 2011, Pages 129-139

  He, Kan ^a   Luettgen, Joseph M ^a   Zhang, Donglu ^a   He, Bing ^a   Grace Jr , James E ^a   Xin, Baomin ^a   Pinto, Donald J P ^a   Wong, Pancras C ^a   Knabb, Robert M ^a   Lam, Patrick Y S ^a   Wexler, Ruth R ^a   Grossman, Scott J ^a  

^a BRISTOL MYERS SQUIBB   (United States)

Author keywords

Anticoagulant; Antithrombotic; Apixaban; Factor Xa

Indexed keywords

APIXABAN; ANTICOAGULANT AGENT; BLOOD CLOTTING FACTOR 10A; PLASMA PROTEIN; PYRAZOLE DERIVATIVE; PYRIDONE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; BLOOD CLOTTING TIME; CHIMPANZEE; CONTROLLED STUDY; DOG; DOSE RESPONSE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG METABOLISM; DRUG PROTEIN BINDING; DRUG STRUCTURE; FEMALE; HUMAN; HUMAN TISSUE; IC 50; IN VITRO STUDY; KIDNEY CLEARANCE; MALE; NONHUMAN; PHARMACODYNAMICS; PLASMA PROTEIN BINDING; PROTHROMBIN TIME; RAT; SINGLE DRUG DOSE; ANIMAL; DRUG ANTAGONISM; METABOLIC CLEARANCE RATE; METABOLISM; PAN TROGLODYTES; PROTEIN BINDING; SPECIES DIFFERENCE;

ANIMALS; ANTICOAGULANTS; BLOOD PROTEINS; DOGS; FACTOR XA; HUMANS; METABOLIC CLEARANCE RATE; PAN TROGLODYTES; PROTEIN BINDING; PYRAZOLES; PYRIDONES; RATS; SPECIES SPECIFICITY; WHOLE BLOOD COAGULATION TIME;

EID: 84856389296     PISSN: 03787966     EISSN: 21070180     Source Type: Journal    
DOI: 10.1007/s13318-011-0037-x     Document Type: Article

References (38)

1. Davies B, Morris T (1993) Physiological parameters in laboratory animals and humans. Pharm Res 10(7):1093-1095 (Pubitemid 23211439)
2. Eriksson BI, Dahl OE, Rosencher N, Kurth AA, Van Dijk CN, Frostick SP, Kälebo P, Christiansen AV, Hantel S, Hettiarachchi R, Schnee J, Büller HR, for the Re-Model Study Group (2007a) Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial. J Thromb Haemost 5(11):2178-2185 (Pubitemid 47617868)
3. Eriksson BI, Dahl OE, Rosencher N, Kurth AA, van Dijk CN, Frostick SP, Prins MH, Hettiarachchi R, Hantel S, Schnee J, Büller HR (2007b) Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial. Lancet 370(9591):949-956 (Pubitemid 47393577)
4. Eriksson BI, Borris LC, Friedman RJ, Haas S, Huisman MV, Kakkar AK, Bandel TJ, Beckmann H, Muehlhofer E, Misselwitz F, Geerts W (2008) Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. N Engl J Med 358(26):2765-2775 (Pubitemid 351930851)
5. Hara T, Yokoyama A, Morishima Y, Kunitada S (1995) Species differences in anticoagulant and anti-Xa activity of DX-9065a, a highly selective factor Xa inhibitor. Thromb Res 80(1):99-104
6. Harder S, Thürmann P (1996) Clinically important drug interactions with anticoagulants: an update. Clin Pharmacokinet 30(6):416-444
7. Hauptmann J, Stürzebecher J (1999) Synthetic inhibitors of thrombin and factor Xa: from bench to bedside. Thromb Res 93(5):203-241 (Pubitemid 29130456)
8. Hemker H, Vermeer C, Govers-Riemslag J (1977) Kinetic aspects of the interaction of blood clotting enzymes. VII. The relation between clotting time and prothrombin concentration. Thromb Haemost 37(1):81-85 (Pubitemid 8059406)
9. Kakkar AK, Brenner B, Dahl OE, Eriksson BI, Mouret P, Muntz J, Soglian AG, Pap AF, Misselwitz F, Haas S (2008) Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial. Lancet 372(9632):31-39
10. Kimmel SE (2008) Warfarin therapy: in need of improvement after all these years. Expert Opin Pharmacother 9(5):677-686 (Pubitemid 351566188)
11. Kubitza D, Becka M, Voith B, Zuehlsdorf M, Wensing G (2005) Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59-7939, an oral, direct factor Xa inhibitor. Clin Pharmacol Ther 78(4):412-421 (Pubitemid 41393676)
12. Lam PYS, Clark CG, Li R, Pinto DJP, Orwat MJ, Galemmo RA, Fevig JM, Teleha CA, Alexander RS, Smallwood AM, Rossi KA, Wright MR, Bai SA, He K, Luettgen JM, Wong PC, Knabb RM, Wexler RR (2003) Structure-based design of novel guanidine/benzamidine mimics: potent and orally bioavailable factor Xa inhibitors as novel anticoagulants. J Med Chem 46(21):4405-4418 (Pubitemid 37238744)
13. Lassen MR, Ageno W, Borris LC, Lieberman JR, Rosencher N, Bandel TJ, Misselwitz F, Turpie AGG (2008) Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty. N Engl J Med 358(26):2776-2786 (Pubitemid 351930852)
14. Lassen MR, Raskob GE, Gallus A, Pineo G, Chen D, Hornick P (2010a) Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised doubleblind trial. Lancet 375(9717):807-815
15. Lassen MR, Gallus A, Raskob GE, Pineo G, Chen D, Ramirez LM (2010b) Apixaban versus enoxaparin for thromboprophylaxis after hip replacement. N Engl J Med 363(26):2487-2498
16. Leadley R (2001) Coagulation factor Xa inhibition: biological background and rationale. Curr Top Med Chem 1(2):151-159
17. Lin JH, Cocchetto DM, Duggan DE (1987) Protein binding as a primary determinant of the clinical pharmacokinetic properties of non-steroidal anti-inflammatory drugs. Clin Pharmacokinet 12(6):402-432
18. Luettgen JM, Knabb RM, He K, Pinto DJP, Rendina AR (2011) Apixaban inhibition of factor Xa: microscopic rate constants and inhibition mechanism in purified protein systems and in human plasma. J Enzyme Inhib Med Chem. doi:10.3109/14756366.2010.535793
19. Obach RS, Baxter JG, Liston TE, Silber BM, Jones BC, Macintyre F, Rance DJ, Wastall P (1997) The prediction of human pharmacokinetic parameters from preclinical and in vitro metabolism data. J Pharmacol Exp Ther 283(1):46-58 (Pubitemid 27438945)
20. Paccaly A, Frick A, Ozoux M-L, Chu V, Rosenburg R, Hinder M, Shukla U, Jensen BK (2006) Pharmacokinetic/pharmacodynamic relationships for otamixaban, a direct factor Xa inhibitor, in healthy subjects. J Clin Pharmacol 46(1):45-51 (Pubitemid 43024118)
21. Pinto DJP, Orwat MJ, Wang S, Fevig JM, Quan ML, Amparo E, Cacciola J, Rossi KA, Alexander RS, Smallwood AM, Luettgen JM, Liang L, Aungst BJ, Wright MR, Knabb RM, Wong PC, Wexler RR, Lam PYS (2001) Discovery of 1-[3-(aminomethyl) phenyl]-N-[3-fluoro-20-(methylsulfonyl)-[1,10-biphenyl]-4-yl]-3- (trifluoromethyl)-1H-pyrazole-5-carboxamide (DPC423), a highly potent, selective, and orally bioavailable inhibitor of blood coagulation factor Xa. J Med Chem 44(4):566-578 (Pubitemid 32156098)
22. Pinto DJP, Orwat MJ, Koch S, Rossi KA, Alexander RS, Smallwood A, Wong PC, Rendina AR, Luettgen JM, Knabb RM, He K, Xin B, Wexler RR, Lam PYS (2007) Discovery of 1-(4-Methoxyphenyl)-7-oxo-6-(4-(2-oxopiperidin-1-yl)phenyl)-4,5,6, 7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxamide (apixaban, BMS-562247), a highly potent, selective, efficacious, and orally bioavailable inhibitor of blood coagulation factor Xa. J Med Chem 50(22):5339-5356 (Pubitemid 350057846)
23. Qiao JX, Wang TC, Wang GZ, Cheney DL, He K, Rendina AR, Xin B, Luettgen JM, Knabb RM, Wexler RR, Lam PYS (2007) Enantiopure five-membered cyclicdiamine derivatives as potent and selective inhibitors of factor Xa. Improving in vitro metabolic stability via core modifications. Bioorg Med Chem Lett 17(18):5041-5048 (Pubitemid 47259674)
24. Quan ML, Wexler RR (2001) The design and synthesis of noncovalent factor Xa inhibitors. Curr Top Med Chem 1(2):137-149
25. Quan ML, Lam PYS, Han Q, Pinto DJP, He MY, Li R, Ellis CD, Clark CG, Teleha CA, Sun J-H, Alexander RS, Bai S, Luettgen JM, Knabb RM, Wong PC, Wexler RR (2005) Discovery of 1-(30-aminobenzisoxazol-50-yl)-3-trifluoromethyl-N-[2- fluoro-4-[(20-dimethylaminomethyl)imidazol-1-yl]phenyl]-1H-pyrazole-5- carboxyamide hydrochloride (razaxaban), a highly potent, selective, and orally bioavailable factor Xa inhibitor. J Med Chem 48(6):1729-1744 (Pubitemid 40396307)
26. Raghavan N, Frost CE, Yu Z, He K, Zhang H, Humphreys WG, Pinto D, Chen S, Bonacorsi S, Wong PC, Zhang D (2009) Apixaban metabolism and pharmacokinetics after oral administration to humans. Drug Metab Disp 37(1):74-81
27. Segel IH (1993) Enzyme kinetics: behavior and analysis of rapid equilibrium and steady-state enzyme systems. Wiley and Sons, New York
28. Stangier J, Rathgen K, Stähle H, Gansser D, Roth W (2007) The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects. Br J Clin Pharmacol 64(3):292-303 (Pubitemid 47283865)
29. Svensson CK, Woodruff MN, Baxter JG, Lalka D (1986) Free drug concentration monitoring in clinical practice: rationale and current status. Clin Pharmacokinet 11(6):450-469 (Pubitemid 17203068)
30. Tobu M, Iqbal O, Hoppensteadt DA, Shultz C, Jeske W, Fareed J (2002) Effects of a synthetic factor Xa inhibitor (JTV-803) on various laboratory tests. Clin Appl Thromb Hemost 8(4):325-336 (Pubitemid 36008756)
31. Turpie AGG (2004) Fondaparinux: a Factor Xa inhibitor for antithrombotic therapy. Expert Opin Pharmacother 5(6):1373-1384 (Pubitemid 38885795)
32. Walenga JM, Hoppensteadt DA (2004) Monitoring the new antithrombotic drugs. Semin Thromb Hemost 30(6):683-695 (Pubitemid 40041604)
33. Wang L, Zhang D, Raghavan N, Yao M, Ma L, Frost CA, Maxwell BD, Chen S-Y, He K, Goosen TC, Griffith WH, Grossman SJ (2010) In vitro assessment of metabolic drug-drug interaction potential of apixaban through cytochrome P450 phenotyping, inhibition, and induction studies. Drug Metab Disp 38(3):448-458
34. Weitz JI (2006) Emerging anticoagulants for the treatment of venous thromboembolism. Thromb Haemost 96(3):274-284 (Pubitemid 44377809)
35. Wong PC, Crain EJ, Watson CA, Zaspel AM, Wright MR, Lam PY, Pinto DJP, Wexler RR, Knabb RM (2002) Nonpeptide factor Xa inhibitors III: effects of DPC423, an orally-active pyrazole antithrombotic agent, on arterial thrombosis in rabbits. J Pharmacol Exp Ther 303(3):993-1000 (Pubitemid 35424381)
36. Wong H, Grossman SJ, Bai SA, Diamond S, Wright MR, Grace JE, Qian M, He K, Yeleswaram K, Christ DD (2004) The chimpanzee (Pan troglodytes) as a pharmacokinetic model for selection of drug candidates: model characterization and application. Drug Metab Disp 32(12):1359-1369 (Pubitemid 39564555)
37. Wong PC, Crain EJ, Xin B, Wexler RR, Lam PYS, Pinto DJ, Luettgen JM, Knabb RM (2008) Apixaban, an oral, direct and highly selective factor Xa inhibitor: in vitro, antithrombotic and antihemostatic studies. J Thromb Haemost 6(5):820-829 (Pubitemid 351524543)
38. Zhang D, He K, Raghavan N, Wang L, Mitroka J, Maxwell BD, Knabb RM, Frost C, Schuster A, Hao F, Gu Z, Humphreys WG, Grossman SJ (2009) Comparative metabolism of 14C-labeled apixaban in mice, rats, rabbits, dogs, and humans. Drug Metab Disp 37(8):1738-1748